Moberg Pharma（MOBS）株式概要Moberg Pharma AB (publish)は製薬会社で、主にスウェーデンで医療用製品を開発・販売している。 詳細MOBS ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長5/6過去の実績0/6財務の健全性5/6配当金0/6報酬当社が推定した公正価値より94.1%で取引されている 収益は年間107.49%増加すると予測されています リスク分析収益が 100 万ドル未満 ( SEK10M )株式の流動性は非常に低い 過去1年間で株主の希薄化は大幅に進んだ 意味のある時価総額がありません ( SEK414M )すべてのリスクチェックを見るMOBS Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueSEK Current PriceSEK 17.55705.0% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-551m439m2016201920222025202620282031Revenue SEK 165.3mEarnings SEK 24.2mAdvancedSet Fair ValueView all narrativesMoberg Pharma AB (publ) 競合他社Shield TherapeuticsSymbol: AIM:STXMarket cap: UK£65.7mECO Animal Health GroupSymbol: AIM:EAHMarket cap: UK£59.6mFutura MedicalSymbol: AIM:FUMMarket cap: UK£2.9mAnimalcare GroupSymbol: AIM:ANCRMarket cap: UK£228.9m価格と性能株価の高値、安値、推移の概要Moberg Pharma過去の株価現在の株価SEK 17.5552週高値SEK 34.7452週安値SEK 17.55ベータ0.901ヶ月の変化0%3ヶ月変化n/a1年変化4.15%3年間の変化n/a5年間の変化-89.81%IPOからの変化-96.66%最新ニュースお知らせ • Jun 15Moberg Pharma Reports Progress On Commercial Launch Preparations For MOB-015 (Terclara)Moberg Pharma AB (publ) announced that the first European countries have approved the rebranding of MOB-015 (Terclara) to Karo Healthcare AB's brand. The approvals provide a defined timeline for launch preparations and marketing activities, with first deliveries planned around year-end. Launch preparations are also progressing in Israel, where the first patients are expected to gain access to the product during the third quarter of this year. Moberg Pharma's partner, Padagis, obtained marketing approval from the Israeli Ministry of Health in December 2025 and has since carried out pre-launch activities, including presentation of MOB-015 at the 3rd International Conference on Nail Disorders in Tel Aviv. Israel will be the first market where the drug MOB-015 (Terclara) is launched outside the Nordic region. As in the Nordics, the product is being launched under Moberg Pharma's brand Terclara in Israel. The first commercial deliveries are planned for the third quarter. Within the framework of the collaboration with Karo Healthcare, local approvals of updated product information and packaging materials are now ongoing. Following these approvals, commercial production can commence while launch activities are intensified, including sell-in efforts with pharmacy chains and pharmaceutical wholesalers. Karo Healthcare is leveraging its established antifungal franchise, including the Lamisil brand, and its broad European commercial platform with established distribution in all major pharmacy chains to support the rollout of MOB-015 across the region. Launch timing will subsequently depend primarily on local lead times, pharmacy chain launch windows and other market-specific conditions. The first commercial deliveries are planned around year-end, enabling start of consumer marketing activities ahead of the high season. As previously communicated, as a result of local regulatory conditions, the Lamisil brand will not be available in all markets covered by the collaboration between Moberg Pharma and Karo Healthcare, however the product will be launched using a similar visual identity and recognition factor in markets where other brands are used. In addition to Lamisil, Pevaryl, an antifungal brand within Karo Healthcare's portfolio with a strong local market position, will also be used. The companies' assessment is that the regulatory process for the approval of drug names is generally more complex in several Western European countries than in the other countries covered by the collaboration. Karo Healthcare and Moberg Pharma collaborate across 19 European markets as well as Australia, New Zealand, South Korea, Taiwan and China. The companies expect that the Lamisil brand will be used across the majority of these markets. Nail fungus is a common infection affecting approximately 10% of the general population, with the majority of patients currently untreated. The global market potential is significant, with more than hundred million patients worldwide and a clear demand for improved products. Moberg Pharma estimates the annual worldwide peak sales potential for MOB-015/Terclara to be in the range of USD 250 million to USD 500 million. MOB-015/Terclara, developed by Moberg Pharma, represents the next generation of terbinafine treatment--a novel topical formulation. Oral treatments for nail fungus are associated with risks such as drug interactions and liver damage, which are avoided with topical treatment. Previous attempts at topical terbinafine treatment have failed due to the difficulty of delivering sufficient amounts of active substance through the nail. MOB-015 is the first topical treatment to achieve mycological cure rates comparable to oral therapy; mycological cure (fungal eradication) was achieved in 76% of patients in pivotal studies, and the product has received market approval in 14 countries.お知らせ • May 23Moberg Pharma AB (Publ) Approves the Election of Board MembersOn May 21, 2026. Moberg Pharma AB (publ) held its Annual General Meeting. The Annual General Meeting resolved, in accordance with the proposal of the shareholder Noster Capital Master Fund Limited ("Noster Capital"), on election of Lars Johansson, Jack Bradley and Daniel Kaufman as board members, all for the period until the end of the next Annual General Meeting. Lars Johansson was elected, in accordance with the proposal of both the Nomination Committee and Noster Capital, as the new Chairman of the Board for the period until the end of the next Annual General Meeting. Lars Johansson, born 1966, has over 30 years of experience in pharmaceuticals and medtech. Lars Johansson has held leading roles within the J&J Group with increasing business area responsibility, including as CEO of the Nordic operations (Johnson & Johnson AB 2011-2019, and Janssen AB 2019-2021). Lars Johansson has also held board positions in Schain Research AB, ProstaLund AB, RLS AB, and Läkemedelsindustriföreningen (the Swedish Association of the Pharmaceutical Industry). Lars Johansson holds a master's degree in business administration from Växjö University. Lars Johansson is currently a board member of Ciencia Research and Carponovum AB. Lars Johansson holds no shares in the Company and is independent in relation to the Company, its management, and major shareholders.Jack Bradley, born 1991, has more than a decade of experience in the investment management business. He joined Noster Capital in 2014, and became a Partner and Head of Research in 2017 covering a broad geographical and market-cap investment universe, frequently giving input to company management teams on investor communication and investor relations strategy. He holds a degree in modern history from the University of Oxford. He is a resident of Norway and a British Citizen. Jack Bradley holds no shares in the Company, but Noster Capital (where he is a Partner) holds 3 055 423 shares in the Company. Jack Bradley is independent in relation to the Company, its management, and major shareholders.Daniel Kaufman, born 1968, has been a serial entrepreneur for the past 35 years, starting over a dozen companies, mostly in the technology sector. In the past 6 years, he shifted his focus to investing in public companies, with a focus on small cap value, and a recent large concentration in healthcare. Over these 6 years, his investment returns have exceeded 50% annually. He currently holds 5%+ positions in Harrow Inc. (HROW), Delcath Systems Inc. (DCTH) and Abeona Therapeutics (ABEO). Daniel Kaufman graduated from Williams College with a degree in political economy. Daniel Kaufman holds 1 409 456 shares in the Company and is independent in relation to the Company, its management, and major shareholders.お知らせ • Mar 13Moberg Pharma AB Secures Additional Terbinafine Supplier For Mob-015Moberg Pharma AB announced that an additional supplier of terbinafine has been approved for MOB-015 (drug for nail fungus). The regulatory approval process, initiated in April 2024, has now been positively completed. As a result, Moberg Pharma has thereby secured two alternative suppliers of terbinafine, each with the capacity to meet the company's global demand for terbinafine. This is in line with the company's overall quality efforts, ensuring a stable supply of the active ingredient.お知らせ • Nov 28+ 3 more updatesMoberg Pharma AB (publ) to Report Q2, 2026 Results on Aug 13, 2026Moberg Pharma AB (publ) announced that they will report Q2, 2026 results on Aug 13, 2026お知らせ • Oct 31Moberg Pharma AB (publ), Annual General Meeting, May 21, 2026Moberg Pharma AB (publ), Annual General Meeting, May 21, 2026.お知らせ • Sep 30Moberg Pharma AB (publ) Approves Board ElectionsMoberg Pharma AB (publ) at its Extraordinary General Meeting held on September 29, 2025 approved the election of Fredrik Blom and Mona Zhang as new members of the Board of Directors for the period until the end of the next Annual General Meeting. Thus, the Board of Directors of the Company will, for the period until the next Annual General Meeting, consist of Jonas Ekblom (chairman of the board of directors), Nikolaj Sörensen, Isabelle Ducellier, Otto Skolling, Richard Ding, Fredrik Blom and Mona Zhang.Mona Zhang was born in 1981 and holds an MBA from Rotman and a bachelor's degree in electrical engineering from Beijing Institute of Technology. Mona Zhang has more than 15 years of experience in global investment management and corporate governance. Mona is the Founder and Managing Partner of Trunity Partners Ltd., a portfolio management firm registered with the Ontario Securities Commission in Canada, where she is responsible for capital allocation, operations, and compliance. Previously, she worked at Mackenzie Investments as a Portfolio Manager on the Global Equity and Income Team, focusing on investment research, portfolio construction, and risk oversight. Earlier in her career, she was with Burgundy Asset Management, specializing in international equity analysis. Today, Mona serves on the Boards of the Canadian Business History Association and the International Agama Zen Practice Centre. She is also a guest lecturer at the Rotman School of Management, University of Toronto. She is a CFA charterholder. Mona holds no shares in the Company as of the day of this notice and is independent in relation to the Company, its management and major shareholders.Fredrik Blom was born in 1970 and holds a master's degree in financial economics from Stockholm University. Throughout his professional career, Fredrik has primarily worked in sales, often within entrepreneurially driven companies. He has co-founded several companies, one of them is Svenska Studenthus, a real estate company focused on rental and student housing, which merged with K2A Fastigheter prior to the company's IPO on Nasdaq Stockholm in 2019. Fredrik has extensive experience in starting companies and developing their initial cash flows. Other companies Fredrik has co-founded and served on the board of include Jeff Fastigheter and RAW Properties. Fredrik holds 926,000 shares in the Company, directly and indirectly, as of the day of this notice. Fredrik is independent in relation to the Company, its management and major shareholders.最新情報をもっと見るRecent updatesお知らせ • Jun 15Moberg Pharma Reports Progress On Commercial Launch Preparations For MOB-015 (Terclara)Moberg Pharma AB (publ) announced that the first European countries have approved the rebranding of MOB-015 (Terclara) to Karo Healthcare AB's brand. The approvals provide a defined timeline for launch preparations and marketing activities, with first deliveries planned around year-end. Launch preparations are also progressing in Israel, where the first patients are expected to gain access to the product during the third quarter of this year. Moberg Pharma's partner, Padagis, obtained marketing approval from the Israeli Ministry of Health in December 2025 and has since carried out pre-launch activities, including presentation of MOB-015 at the 3rd International Conference on Nail Disorders in Tel Aviv. Israel will be the first market where the drug MOB-015 (Terclara) is launched outside the Nordic region. As in the Nordics, the product is being launched under Moberg Pharma's brand Terclara in Israel. The first commercial deliveries are planned for the third quarter. Within the framework of the collaboration with Karo Healthcare, local approvals of updated product information and packaging materials are now ongoing. Following these approvals, commercial production can commence while launch activities are intensified, including sell-in efforts with pharmacy chains and pharmaceutical wholesalers. Karo Healthcare is leveraging its established antifungal franchise, including the Lamisil brand, and its broad European commercial platform with established distribution in all major pharmacy chains to support the rollout of MOB-015 across the region. Launch timing will subsequently depend primarily on local lead times, pharmacy chain launch windows and other market-specific conditions. The first commercial deliveries are planned around year-end, enabling start of consumer marketing activities ahead of the high season. As previously communicated, as a result of local regulatory conditions, the Lamisil brand will not be available in all markets covered by the collaboration between Moberg Pharma and Karo Healthcare, however the product will be launched using a similar visual identity and recognition factor in markets where other brands are used. In addition to Lamisil, Pevaryl, an antifungal brand within Karo Healthcare's portfolio with a strong local market position, will also be used. The companies' assessment is that the regulatory process for the approval of drug names is generally more complex in several Western European countries than in the other countries covered by the collaboration. Karo Healthcare and Moberg Pharma collaborate across 19 European markets as well as Australia, New Zealand, South Korea, Taiwan and China. The companies expect that the Lamisil brand will be used across the majority of these markets. Nail fungus is a common infection affecting approximately 10% of the general population, with the majority of patients currently untreated. The global market potential is significant, with more than hundred million patients worldwide and a clear demand for improved products. Moberg Pharma estimates the annual worldwide peak sales potential for MOB-015/Terclara to be in the range of USD 250 million to USD 500 million. MOB-015/Terclara, developed by Moberg Pharma, represents the next generation of terbinafine treatment--a novel topical formulation. Oral treatments for nail fungus are associated with risks such as drug interactions and liver damage, which are avoided with topical treatment. Previous attempts at topical terbinafine treatment have failed due to the difficulty of delivering sufficient amounts of active substance through the nail. MOB-015 is the first topical treatment to achieve mycological cure rates comparable to oral therapy; mycological cure (fungal eradication) was achieved in 76% of patients in pivotal studies, and the product has received market approval in 14 countries.お知らせ • May 23Moberg Pharma AB (Publ) Approves the Election of Board MembersOn May 21, 2026. Moberg Pharma AB (publ) held its Annual General Meeting. The Annual General Meeting resolved, in accordance with the proposal of the shareholder Noster Capital Master Fund Limited ("Noster Capital"), on election of Lars Johansson, Jack Bradley and Daniel Kaufman as board members, all for the period until the end of the next Annual General Meeting. Lars Johansson was elected, in accordance with the proposal of both the Nomination Committee and Noster Capital, as the new Chairman of the Board for the period until the end of the next Annual General Meeting. Lars Johansson, born 1966, has over 30 years of experience in pharmaceuticals and medtech. Lars Johansson has held leading roles within the J&J Group with increasing business area responsibility, including as CEO of the Nordic operations (Johnson & Johnson AB 2011-2019, and Janssen AB 2019-2021). Lars Johansson has also held board positions in Schain Research AB, ProstaLund AB, RLS AB, and Läkemedelsindustriföreningen (the Swedish Association of the Pharmaceutical Industry). Lars Johansson holds a master's degree in business administration from Växjö University. Lars Johansson is currently a board member of Ciencia Research and Carponovum AB. Lars Johansson holds no shares in the Company and is independent in relation to the Company, its management, and major shareholders.Jack Bradley, born 1991, has more than a decade of experience in the investment management business. He joined Noster Capital in 2014, and became a Partner and Head of Research in 2017 covering a broad geographical and market-cap investment universe, frequently giving input to company management teams on investor communication and investor relations strategy. He holds a degree in modern history from the University of Oxford. He is a resident of Norway and a British Citizen. Jack Bradley holds no shares in the Company, but Noster Capital (where he is a Partner) holds 3 055 423 shares in the Company. Jack Bradley is independent in relation to the Company, its management, and major shareholders.Daniel Kaufman, born 1968, has been a serial entrepreneur for the past 35 years, starting over a dozen companies, mostly in the technology sector. In the past 6 years, he shifted his focus to investing in public companies, with a focus on small cap value, and a recent large concentration in healthcare. Over these 6 years, his investment returns have exceeded 50% annually. He currently holds 5%+ positions in Harrow Inc. (HROW), Delcath Systems Inc. (DCTH) and Abeona Therapeutics (ABEO). Daniel Kaufman graduated from Williams College with a degree in political economy. Daniel Kaufman holds 1 409 456 shares in the Company and is independent in relation to the Company, its management, and major shareholders.お知らせ • Mar 13Moberg Pharma AB Secures Additional Terbinafine Supplier For Mob-015Moberg Pharma AB announced that an additional supplier of terbinafine has been approved for MOB-015 (drug for nail fungus). The regulatory approval process, initiated in April 2024, has now been positively completed. As a result, Moberg Pharma has thereby secured two alternative suppliers of terbinafine, each with the capacity to meet the company's global demand for terbinafine. This is in line with the company's overall quality efforts, ensuring a stable supply of the active ingredient.お知らせ • Nov 28+ 3 more updatesMoberg Pharma AB (publ) to Report Q2, 2026 Results on Aug 13, 2026Moberg Pharma AB (publ) announced that they will report Q2, 2026 results on Aug 13, 2026お知らせ • Oct 31Moberg Pharma AB (publ), Annual General Meeting, May 21, 2026Moberg Pharma AB (publ), Annual General Meeting, May 21, 2026.お知らせ • Sep 30Moberg Pharma AB (publ) Approves Board ElectionsMoberg Pharma AB (publ) at its Extraordinary General Meeting held on September 29, 2025 approved the election of Fredrik Blom and Mona Zhang as new members of the Board of Directors for the period until the end of the next Annual General Meeting. Thus, the Board of Directors of the Company will, for the period until the next Annual General Meeting, consist of Jonas Ekblom (chairman of the board of directors), Nikolaj Sörensen, Isabelle Ducellier, Otto Skolling, Richard Ding, Fredrik Blom and Mona Zhang.Mona Zhang was born in 1981 and holds an MBA from Rotman and a bachelor's degree in electrical engineering from Beijing Institute of Technology. Mona Zhang has more than 15 years of experience in global investment management and corporate governance. Mona is the Founder and Managing Partner of Trunity Partners Ltd., a portfolio management firm registered with the Ontario Securities Commission in Canada, where she is responsible for capital allocation, operations, and compliance. Previously, she worked at Mackenzie Investments as a Portfolio Manager on the Global Equity and Income Team, focusing on investment research, portfolio construction, and risk oversight. Earlier in her career, she was with Burgundy Asset Management, specializing in international equity analysis. Today, Mona serves on the Boards of the Canadian Business History Association and the International Agama Zen Practice Centre. She is also a guest lecturer at the Rotman School of Management, University of Toronto. She is a CFA charterholder. Mona holds no shares in the Company as of the day of this notice and is independent in relation to the Company, its management and major shareholders.Fredrik Blom was born in 1970 and holds a master's degree in financial economics from Stockholm University. Throughout his professional career, Fredrik has primarily worked in sales, often within entrepreneurially driven companies. He has co-founded several companies, one of them is Svenska Studenthus, a real estate company focused on rental and student housing, which merged with K2A Fastigheter prior to the company's IPO on Nasdaq Stockholm in 2019. Fredrik has extensive experience in starting companies and developing their initial cash flows. Other companies Fredrik has co-founded and served on the board of include Jeff Fastigheter and RAW Properties. Fredrik holds 926,000 shares in the Company, directly and indirectly, as of the day of this notice. Fredrik is independent in relation to the Company, its management and major shareholders.お知らせ • Jun 25Moberg Pharma AB (Publ) Announces Management ChangesMoberg Pharma AB (publ) announced that in connection with the reorganization, Anders Bröijersén, Chief Medical Officer, and Robert Ehrl, Head of Supply, are leaving Moberg Pharma and the management team. Going forward, supply is incorporated into Christina Erixon's existing area of responsibility. The company's medical expertise is secured through consultants. Following these changes, Moberg Pharma's management team consists of Anna Ljung, Mark Beveridge, Annica Magnusson, and Christina Erixon.お知らせ • Dec 18Moberg Pharma AB (Publ) Secures New Terbinafine SupplierMoberg Pharma AB (publ) announces that a new terbinafine supplier has been secured for MOB-015 (drug for nail fungus). As a result, terbinafine availability is no longer a limiting factor for the company's launch plans. Over the past year, Moberg Pharma qualified a new terbinafine manufacturer with an authorized EU Certificate of Suitability (CEP) now available for MOB-015. Three product batches have been produced using terbinafine from the new supplier where available stability data confirm the shelf-life profile of MOB-015. The status is unchanged for the previously communicated approval process regarding the first additional terbinafine supplier, submitted in April. Moberg Pharma has earlier responded to all questions received from the Medical Products Agency and awaits the agency´s decision. As a result, Moberg Pharma expects to have several alternate terbinafine suppliers secured in the near future. Each of these suppliers has the capacity to meet the company's global terbinafine demand.お知らせ • Nov 08Moberg Pharma AB (publ), Annual General Meeting, May 22, 2025Moberg Pharma AB (publ), Annual General Meeting, May 22, 2025.お知らせ • Oct 23+ 2 more updatesMoberg Pharma AB (publ) to Report First Half, 2025 Results on Aug 12, 2025Moberg Pharma AB (publ) announced that they will report first half, 2025 results on Aug 12, 2025お知らせ • Oct 11Moberg Pharma AB (publ) to Report Fiscal Year 2024 Results on Feb 11, 2025Moberg Pharma AB (publ) announced that they will report fiscal year 2024 results on Feb 11, 2025お知らせ • Sep 13Moberg Pharma AB (publ) Receives Information About Clinical Cure in a Subset of Patients in the Ongoing North American Phase 3 Study for MOB-015 Against Nail FungusMoberg Pharma AB (publ) announced that the company has received information about clinical cure in a subset of patients in the ongoing North American Phase 3 study for MOB-015 against nail fungus. The number of patients who have achieved clinical cure in this blinded subset of patients is lower than the company's expectations, which necessitates that Moberg Pharma inform the market about this fact. The North American Phase 3 study is ongoing at 33 study centers in the US and Canada, including a total of 384 patients. The study constitutes an essential part of the clinical data required for the registration and commercialization of MOB-015 in the US and differs from previous studies with MOB-015, which is the basis for drug approval in 13 EU countries, by reducing the dosage - 8 weeks daily dosing followed by weekly maintenance treatment for 40 weeks, compared to daily dosing throughout the entire treatment period. In the process of preparing the database for upcoming topline data, the company has received information regarding clinical cure in a subset of patients in the study. Clinical cure is one of three parameters that together constitute the study's primary treatment goal, complete cure. All three parameters; clinical cure, negative fungal culture, and negative microscopy, need to be met for a patient to be considered completely cured. No information has been obtained about the other study parameters included in complete cure. The information obtained is blinded; no information has been received regarding which patient received active treatment or how many patients in the data subset received active treatment (patients in the study are randomized 2:1 to treatment with MOB-015 and vehicle). The total number of patients who have achieved clinical cure in this subset of patients is lower than the company's expectations, and Moberg Pharma assesses that the risk of not being able to commercialize the product in the US based on this study has significantly increased, which requires the company to inform the market of this fact. It is an absolute priority to protect the integrity of the study data, both as not to undermine the possibilities of using study results in discussions with regulatory authorities, and as there are patients with ongoing treatment in the study. Moberg Pharma will not speculate on possible outcomes or what this means for the future potential of MOB-015 and will await topline results to avoid drawing premature conclusions.お知らせ • May 16Moberg Pharma AB (Publ) Elects Jonas Ekblom as Board MemberMoberg Pharma AB (publ) at its Annual General Meeting held on May 14, 2024, approved the election of Jonas Ekblom as board member for a period until the end of the next Annual General Meeting.お知らせ • May 08Moberg Pharma AB Announces MOB-015 Receives National Approvals for All Countries Included in the Decentralized ProcedureMoberg Pharma AB announced that MOB-015 has received national approvals for all countries included in the decentralized procedure. MOB-015 is thus approved for the treatment of mild to moderate fungal infections of the nails in adults in 13 European countries. National approvals follow the completion of the decentralized procedure with a positive result where MOB-015 is recommended for approval in 13 European countries. The following EU countries are included: Austria, Belgium, Czech Republic, Denmark, Finland, France, Hungary, Ireland, Italy, Netherlands, Norway, Spain and Sweden. MOB-015 can be obtained with a prescription (Rx) in the Czech Republic, Denmark, Finland, France, Ireland and Spain, while it's approved as a non-prescription medicinal product, i.e. over-the-counter (OTC) in Austria, Belgium, Hungary, Italy, the Netherlands, Norway and Sweden.Breakeven Date Change • Mar 28Forecast to breakeven in 2026The analyst covering Moberg Pharma expects the company to break even for the first time. New forecast suggests the company will make a profit of kr5.00m in 2026. Average annual earnings growth of 48% is required to achieve expected profit on schedule.Board Change • Mar 28High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 5 experienced directors. No highly experienced directors. Independent Director Nikolaj Sorensen is the most experienced director on the board, commencing their role in 2021. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.Board Change • Mar 02High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 5 experienced directors. No highly experienced directors. Independent Director Nikolaj Sorensen is the most experienced director on the board, commencing their role in 2021. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.Board Change • Feb 07High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 5 experienced directors. No highly experienced directors. Independent Director Nikolaj Sorensen is the most experienced director on the board, commencing their role in 2021. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.Board Change • Jan 08High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 5 experienced directors. No highly experienced directors. Independent Director Nikolaj Sorensen is the most experienced director on the board, commencing their role in 2021. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.Board Change • Dec 12High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 5 experienced directors. No highly experienced directors. Independent Director Nikolaj Sorensen is the most experienced director on the board, commencing their role in 2021. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.お知らせ • Nov 09Moberg Pharma Announces Leadership ChangesMoberg Pharma AB is strengthening its organization following market approval earlier this year and in preparation for the upcoming launch. The management team is welcoming two new members, Christina Erixon, Head of Pharmaceutical Development & Operations, who is replacing Agneta Larhed, and Robert Ehrl, Head of Supply, who is taking over from Jesper Lind. Both roles have been expanded from part-time consultants to full-time positions. Agneta Larhed is leaving the executive team but will remain a part-time consultant to the company with unchanged scope. Jesper Lind will also remain as a consultant to the company for a period. Christina Erixon has a broad experience of development, regulatory and quality within the pharmaceutical industry. Dr. Erixon has held leading positions within the pharmaceutical industry and at regulatory authorities, including roles as the manager of clinical trials at the Swedish Medical Products Agency, senior product developer at AstraZeneca, business manager and associate director for Pharmaceutical Development at APL, and most recently as the director of Drug Development at SDS Life Science. Dr. Erixon is a pharmacist with a doctoral degree in pharmaceutics from Uppsala University. Robert Ehrl holds a Ph.D. in organic chemist with over 20 years of experience in the pharmaceutical industry. He has held leadership positions at AstraZeneca and Valneva Sweden AB, primarily in process development, supply, and manufacturing. Dr. Ehrl has worked with both small molecule and biological drugs/vaccines, from active pharmaceutical ingredient (API) to final packed product.お知らせ • Oct 19Moberg Pharma AB (publ) Appoints Nomination CommitteeMoberg Pharma AB (publ) appointed nomination committee. It comprises of Gillis Cullin, appointed by Östersjöstiftelsen, Ida Marie Lindberg, appointed by Kjelsmark Holding, Kerstin Valinder Strinnholm, Chairman of the Board.お知らせ • Oct 06Moberg Pharma Completes Enrollment to the Phase 3 Study for Mob-015 in North AmericaMoberg Pharma AB has completed the recruitment of 384 patients with onychomycosis (nail fungus) for the ongoing MOB-015 phase 3 study in North America. The aim is to provide a pivotal part of the clinical data set for registration and commercialization of MOB-015 in the U.S. Topline results are expected in January 2025. The enrollment to the North American study has now been completed with 384 patients randomized at 33 sites in the U.S. and Canada. Topline results are expected in January 2025. The patients are evaluated over 52 weeks and the primary endpoint is the proportion of subjects achieving complete cure of their target nail. The study design builds on the experience gained from the previous Phase 3 studies. Moberg Pharma cooperate with the same CRO, lead investigator and successful sites from the previous North American study. The purpose of the study is to facilitate market approval in the US as well as strengthen the product's clinical evidence and marketing claims globally.New Risk • Aug 13New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: kr97.8m (US$9.03m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings are forecast to decline by an average of 43% per year for the foreseeable future. Revenue is less than US$1m (kr207k revenue, or US$19k). Market cap is less than US$10m (kr97.8m market cap, or US$9.03m).お知らせ • Aug 05Moberg Pharma AB (publ) Announces National Approval for MOB-015 in SwedenMoberg Pharma AB announced that MOB-015 has received national approval for the company's home market, Sweden, for the treatment of mild to moderate fungal infections of the nails in adults. This is the second country to grant national approval for MOB-015, following the approval in Ireland announced July 31st, and Sweden is the first country where MOB-015 has been approved for over-the-counter (OTC) use. Grant of market authorization in Sweden is significant as commercialization rollout is planned to start in home market. The company will initiate the launch as quickly as possible and expect to initiate launch preparations in Sweden before the end of the year. National approvals follow the completion of the decentralized procedure with a positive outcome, where MOB-015 was recommended for national approval in 13 European countries. The following countries are included: Austria, Belgium, Czech Republic, Denmark, Finland, France, Hungary, Ireland, Italy, Netherlands, Norway, Spain and Sweden. Currently, national implementation in each country and granting of marketing authorizations including OTC-approvals when applicable, is ongoing. National approvals are expected to occur in the coming months and timelines may vary between countries.お知らせ • Aug 04+ 5 more updatesMoberg Pharma AB (publ) to Report Fiscal Year 2023 Final Results on Apr 16, 2024Moberg Pharma AB (publ) announced that they will report fiscal year 2023 final results on Apr 16, 2024お知らせ • Aug 02Moberg Pharma AB Announces That Mob-015 Has Receives National Approval in Ireland for the Treatment of Mild to Moderate Fungal Infections of the Nails in AdultsMoberg Pharma AB announces that MOB-015 has received national approval in Ireland for the treatment of mild to moderate fungal infections of the nails in adults. Ireland is the first country to grant market authorization for Moberg Pharma's new onychomycosis treatment after the Decentralized Procedure concluded with a positive outcome, where MOB-015 was recommended for national approval in 13 European countries, see press release from June 28th 2023. The Decentralized Procedure includes the following EU countries: Austria, Belgium, Czech Republic, Denmark, Finland, France, Hungary, Ireland, Italy, Netherlands, Norway, Spain and Sweden. Currently, national implementation in each country and granting of marketing authorizations including OTC-approvals when applicable, is ongoing. National approvals are expected to follow during upcoming months and timelines may vary between countries.Board Change • Aug 01High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 5 experienced directors. No highly experienced directors. Independent Director Nikolaj Sorensen is the most experienced director on the board, commencing their role in 2021. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.お知らせ • Jul 06Moberg Pharma AB (publ) Announces Approval for Mob-015 in the European UnionCipher Pharmaceuticals Inc. announced that the Company's partner, Moberg Pharma AB, has obtained European Union approval for MOB-015 (nail fungus treatment) as a result of demonstrating superior levels of mycological cure (76% vs. 42% for comparators) and a significantly better complete cure rate. MOB-015 has been recommended for national approval in 13 European countries, which will be commercialized through partners such as Bayer and Allderma, and is expected to be launched in Nordic countries such as Sweden during 2023. Cipher holds the exclusive Canadian rights to MOB-015, a new topical treatment of Onychomycosis (nail fungus) based on Moberg's patented proprietary formulation of terbinafine. In Canada, according to IQVIA, the total prescription market for Onychomycosis was greater than $82 million at December 31, 2022 with a single product having over 90% market share. Moberg Pharma continues to invest and advance MOB-015 through an additional phase 3 trial of a total of 350 patients with sites across the United States and Canada. The purpose of this study is to facilitate market approval in North America as well as further strengthen the product's clinical evidence beyond the mycological and complete cure rates already demonstrated to the European Union. Patient enrollment in the clinical trial is progressing according to plan with full enrollment expected in 2023.お知らせ • Jun 29Moberg Pharma AB (Publ) Recommends for Approval in EUMoberg Pharma AB announced that the Decentralized Procedure hasended with a positive outcome and that MOB-015 is recommended for national approval in 13 European countries for the treatment of mild to moderate fungal infections of the nails in adults. The approval in the European Union represents the first marketing authorizations for MOB-015's new onychomycosis treatment worldwide. Approval is supported by two Phase 3 trials where MOB-015 demonstrated superior levels of mycological cure (76% vs up to 42% for comparators), and a significantly better complete cure rate compared to vehicle, without any serious adverse reactions. MOB-015 is a topical formulation of terbinafine, enabling effective concentrations of terbinafine to the nail and nail bed while avoiding the risk of systemic exposure seen with oral terbinafine use. The Decentralized Procedure includes the following EU countries: Austria, Belgium, Czech Republic, Denmark, Finland, France, Hungary, Ireland, Italy, Netherlands, Norway, Spain and Sweden. Next steps include national implementation in each country and granting of marketing authorizations including OTC-approvals when applicable. National approvals are expected to follow during upcoming months and timelines may vary between countries.お知らせ • May 17Moberg Pharma AB (Publ) Elects Håkan Wallin to the Board MembersMoberg Pharma AB (publ) announced at annual general meeting held on May 16, 2023, the shareholders elected Håkan Wallin as board members for a period until the end of the next Annual General Meeting.Board Change • Sep 26Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Director Mattias Klintemar was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Aug 25Moberg Pharma AB (publ) to Report First Half, 2023 Results on Aug 15, 2023Moberg Pharma AB (publ) announced that they will report first half, 2023 results on Aug 15, 2023株主還元MOBSGB PharmaceuticalsGB 市場7D0%6.1%0.2%1Y4.2%33.5%18.1%株主還元を見る業界別リターン: MOBS過去 1 年間で33.5 % の収益を上げたUK Pharmaceuticals業界を下回りました。リターン対市場: MOBSは、過去 1 年間で18.1 % のリターンを上げたUK市場を下回りました。価格変動Is MOBS's price volatile compared to industry and market?MOBS volatilityMOBS Average Weekly Movementn/aPharmaceuticals Industry Average Movement5.4%Market Average Movement5.4%10% most volatile stocks in GB Market10.9%10% least volatile stocks in GB Market3.0%安定した株価: MOBSの株価は、 UK市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のMOBSのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト20069Anna Ljungwww.mobergpharma.se製薬会社であるMoberg Pharma AB (publish)は、主にスウェーデンで医療用医薬品の開発・商業化を行っている。MOB-015を開発し、爪真菌の治療薬として第III相臨床試験を完了。同社は以前Moberg Derma AB（publ）として知られていたが、2013年5月にMoberg Pharma AB（publ）に社名を変更した。Moberg Pharma AB（publ）は2006年に設立され、スウェーデンのBrommaに本社を置いている。もっと見るMoberg Pharma AB (publ) 基礎のまとめMoberg Pharma の収益と売上を時価総額と比較するとどうか。MOBS 基礎統計学時価総額SEK 413.94m収益（TTM）-SEK 255.11m売上高(TTM)SEK 9.81m42.2xP/Sレシオ-1.6xPER（株価収益率MOBS は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計MOBS 損益計算書（TTM）収益SEK 9.81m売上原価SEK 3.50m売上総利益SEK 6.32mその他の費用SEK 261.43m収益-SEK 255.11m直近の収益報告Dec 31, 2024次回決算日May 13, 2025一株当たり利益（EPS）-5.46グロス・マージン64.37%純利益率-2,600.25%有利子負債／自己資本比率0%MOBS の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/02/15 21:24終値2024/11/18 00:00収益2024/12/31年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Moberg Pharma AB (publ) 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関Bjorn RydellABG Sundal Collier SponsoredKlas PykNordea MarketsMats HyttingeRedeye1 その他のアナリストを表示
お知らせ • Jun 15Moberg Pharma Reports Progress On Commercial Launch Preparations For MOB-015 (Terclara)Moberg Pharma AB (publ) announced that the first European countries have approved the rebranding of MOB-015 (Terclara) to Karo Healthcare AB's brand. The approvals provide a defined timeline for launch preparations and marketing activities, with first deliveries planned around year-end. Launch preparations are also progressing in Israel, where the first patients are expected to gain access to the product during the third quarter of this year. Moberg Pharma's partner, Padagis, obtained marketing approval from the Israeli Ministry of Health in December 2025 and has since carried out pre-launch activities, including presentation of MOB-015 at the 3rd International Conference on Nail Disorders in Tel Aviv. Israel will be the first market where the drug MOB-015 (Terclara) is launched outside the Nordic region. As in the Nordics, the product is being launched under Moberg Pharma's brand Terclara in Israel. The first commercial deliveries are planned for the third quarter. Within the framework of the collaboration with Karo Healthcare, local approvals of updated product information and packaging materials are now ongoing. Following these approvals, commercial production can commence while launch activities are intensified, including sell-in efforts with pharmacy chains and pharmaceutical wholesalers. Karo Healthcare is leveraging its established antifungal franchise, including the Lamisil brand, and its broad European commercial platform with established distribution in all major pharmacy chains to support the rollout of MOB-015 across the region. Launch timing will subsequently depend primarily on local lead times, pharmacy chain launch windows and other market-specific conditions. The first commercial deliveries are planned around year-end, enabling start of consumer marketing activities ahead of the high season. As previously communicated, as a result of local regulatory conditions, the Lamisil brand will not be available in all markets covered by the collaboration between Moberg Pharma and Karo Healthcare, however the product will be launched using a similar visual identity and recognition factor in markets where other brands are used. In addition to Lamisil, Pevaryl, an antifungal brand within Karo Healthcare's portfolio with a strong local market position, will also be used. The companies' assessment is that the regulatory process for the approval of drug names is generally more complex in several Western European countries than in the other countries covered by the collaboration. Karo Healthcare and Moberg Pharma collaborate across 19 European markets as well as Australia, New Zealand, South Korea, Taiwan and China. The companies expect that the Lamisil brand will be used across the majority of these markets. Nail fungus is a common infection affecting approximately 10% of the general population, with the majority of patients currently untreated. The global market potential is significant, with more than hundred million patients worldwide and a clear demand for improved products. Moberg Pharma estimates the annual worldwide peak sales potential for MOB-015/Terclara to be in the range of USD 250 million to USD 500 million. MOB-015/Terclara, developed by Moberg Pharma, represents the next generation of terbinafine treatment--a novel topical formulation. Oral treatments for nail fungus are associated with risks such as drug interactions and liver damage, which are avoided with topical treatment. Previous attempts at topical terbinafine treatment have failed due to the difficulty of delivering sufficient amounts of active substance through the nail. MOB-015 is the first topical treatment to achieve mycological cure rates comparable to oral therapy; mycological cure (fungal eradication) was achieved in 76% of patients in pivotal studies, and the product has received market approval in 14 countries.
お知らせ • May 23Moberg Pharma AB (Publ) Approves the Election of Board MembersOn May 21, 2026. Moberg Pharma AB (publ) held its Annual General Meeting. The Annual General Meeting resolved, in accordance with the proposal of the shareholder Noster Capital Master Fund Limited ("Noster Capital"), on election of Lars Johansson, Jack Bradley and Daniel Kaufman as board members, all for the period until the end of the next Annual General Meeting. Lars Johansson was elected, in accordance with the proposal of both the Nomination Committee and Noster Capital, as the new Chairman of the Board for the period until the end of the next Annual General Meeting. Lars Johansson, born 1966, has over 30 years of experience in pharmaceuticals and medtech. Lars Johansson has held leading roles within the J&J Group with increasing business area responsibility, including as CEO of the Nordic operations (Johnson & Johnson AB 2011-2019, and Janssen AB 2019-2021). Lars Johansson has also held board positions in Schain Research AB, ProstaLund AB, RLS AB, and Läkemedelsindustriföreningen (the Swedish Association of the Pharmaceutical Industry). Lars Johansson holds a master's degree in business administration from Växjö University. Lars Johansson is currently a board member of Ciencia Research and Carponovum AB. Lars Johansson holds no shares in the Company and is independent in relation to the Company, its management, and major shareholders.Jack Bradley, born 1991, has more than a decade of experience in the investment management business. He joined Noster Capital in 2014, and became a Partner and Head of Research in 2017 covering a broad geographical and market-cap investment universe, frequently giving input to company management teams on investor communication and investor relations strategy. He holds a degree in modern history from the University of Oxford. He is a resident of Norway and a British Citizen. Jack Bradley holds no shares in the Company, but Noster Capital (where he is a Partner) holds 3 055 423 shares in the Company. Jack Bradley is independent in relation to the Company, its management, and major shareholders.Daniel Kaufman, born 1968, has been a serial entrepreneur for the past 35 years, starting over a dozen companies, mostly in the technology sector. In the past 6 years, he shifted his focus to investing in public companies, with a focus on small cap value, and a recent large concentration in healthcare. Over these 6 years, his investment returns have exceeded 50% annually. He currently holds 5%+ positions in Harrow Inc. (HROW), Delcath Systems Inc. (DCTH) and Abeona Therapeutics (ABEO). Daniel Kaufman graduated from Williams College with a degree in political economy. Daniel Kaufman holds 1 409 456 shares in the Company and is independent in relation to the Company, its management, and major shareholders.
お知らせ • Mar 13Moberg Pharma AB Secures Additional Terbinafine Supplier For Mob-015Moberg Pharma AB announced that an additional supplier of terbinafine has been approved for MOB-015 (drug for nail fungus). The regulatory approval process, initiated in April 2024, has now been positively completed. As a result, Moberg Pharma has thereby secured two alternative suppliers of terbinafine, each with the capacity to meet the company's global demand for terbinafine. This is in line with the company's overall quality efforts, ensuring a stable supply of the active ingredient.
お知らせ • Nov 28+ 3 more updatesMoberg Pharma AB (publ) to Report Q2, 2026 Results on Aug 13, 2026Moberg Pharma AB (publ) announced that they will report Q2, 2026 results on Aug 13, 2026
お知らせ • Oct 31Moberg Pharma AB (publ), Annual General Meeting, May 21, 2026Moberg Pharma AB (publ), Annual General Meeting, May 21, 2026.
お知らせ • Sep 30Moberg Pharma AB (publ) Approves Board ElectionsMoberg Pharma AB (publ) at its Extraordinary General Meeting held on September 29, 2025 approved the election of Fredrik Blom and Mona Zhang as new members of the Board of Directors for the period until the end of the next Annual General Meeting. Thus, the Board of Directors of the Company will, for the period until the next Annual General Meeting, consist of Jonas Ekblom (chairman of the board of directors), Nikolaj Sörensen, Isabelle Ducellier, Otto Skolling, Richard Ding, Fredrik Blom and Mona Zhang.Mona Zhang was born in 1981 and holds an MBA from Rotman and a bachelor's degree in electrical engineering from Beijing Institute of Technology. Mona Zhang has more than 15 years of experience in global investment management and corporate governance. Mona is the Founder and Managing Partner of Trunity Partners Ltd., a portfolio management firm registered with the Ontario Securities Commission in Canada, where she is responsible for capital allocation, operations, and compliance. Previously, she worked at Mackenzie Investments as a Portfolio Manager on the Global Equity and Income Team, focusing on investment research, portfolio construction, and risk oversight. Earlier in her career, she was with Burgundy Asset Management, specializing in international equity analysis. Today, Mona serves on the Boards of the Canadian Business History Association and the International Agama Zen Practice Centre. She is also a guest lecturer at the Rotman School of Management, University of Toronto. She is a CFA charterholder. Mona holds no shares in the Company as of the day of this notice and is independent in relation to the Company, its management and major shareholders.Fredrik Blom was born in 1970 and holds a master's degree in financial economics from Stockholm University. Throughout his professional career, Fredrik has primarily worked in sales, often within entrepreneurially driven companies. He has co-founded several companies, one of them is Svenska Studenthus, a real estate company focused on rental and student housing, which merged with K2A Fastigheter prior to the company's IPO on Nasdaq Stockholm in 2019. Fredrik has extensive experience in starting companies and developing their initial cash flows. Other companies Fredrik has co-founded and served on the board of include Jeff Fastigheter and RAW Properties. Fredrik holds 926,000 shares in the Company, directly and indirectly, as of the day of this notice. Fredrik is independent in relation to the Company, its management and major shareholders.
お知らせ • Jun 15Moberg Pharma Reports Progress On Commercial Launch Preparations For MOB-015 (Terclara)Moberg Pharma AB (publ) announced that the first European countries have approved the rebranding of MOB-015 (Terclara) to Karo Healthcare AB's brand. The approvals provide a defined timeline for launch preparations and marketing activities, with first deliveries planned around year-end. Launch preparations are also progressing in Israel, where the first patients are expected to gain access to the product during the third quarter of this year. Moberg Pharma's partner, Padagis, obtained marketing approval from the Israeli Ministry of Health in December 2025 and has since carried out pre-launch activities, including presentation of MOB-015 at the 3rd International Conference on Nail Disorders in Tel Aviv. Israel will be the first market where the drug MOB-015 (Terclara) is launched outside the Nordic region. As in the Nordics, the product is being launched under Moberg Pharma's brand Terclara in Israel. The first commercial deliveries are planned for the third quarter. Within the framework of the collaboration with Karo Healthcare, local approvals of updated product information and packaging materials are now ongoing. Following these approvals, commercial production can commence while launch activities are intensified, including sell-in efforts with pharmacy chains and pharmaceutical wholesalers. Karo Healthcare is leveraging its established antifungal franchise, including the Lamisil brand, and its broad European commercial platform with established distribution in all major pharmacy chains to support the rollout of MOB-015 across the region. Launch timing will subsequently depend primarily on local lead times, pharmacy chain launch windows and other market-specific conditions. The first commercial deliveries are planned around year-end, enabling start of consumer marketing activities ahead of the high season. As previously communicated, as a result of local regulatory conditions, the Lamisil brand will not be available in all markets covered by the collaboration between Moberg Pharma and Karo Healthcare, however the product will be launched using a similar visual identity and recognition factor in markets where other brands are used. In addition to Lamisil, Pevaryl, an antifungal brand within Karo Healthcare's portfolio with a strong local market position, will also be used. The companies' assessment is that the regulatory process for the approval of drug names is generally more complex in several Western European countries than in the other countries covered by the collaboration. Karo Healthcare and Moberg Pharma collaborate across 19 European markets as well as Australia, New Zealand, South Korea, Taiwan and China. The companies expect that the Lamisil brand will be used across the majority of these markets. Nail fungus is a common infection affecting approximately 10% of the general population, with the majority of patients currently untreated. The global market potential is significant, with more than hundred million patients worldwide and a clear demand for improved products. Moberg Pharma estimates the annual worldwide peak sales potential for MOB-015/Terclara to be in the range of USD 250 million to USD 500 million. MOB-015/Terclara, developed by Moberg Pharma, represents the next generation of terbinafine treatment--a novel topical formulation. Oral treatments for nail fungus are associated with risks such as drug interactions and liver damage, which are avoided with topical treatment. Previous attempts at topical terbinafine treatment have failed due to the difficulty of delivering sufficient amounts of active substance through the nail. MOB-015 is the first topical treatment to achieve mycological cure rates comparable to oral therapy; mycological cure (fungal eradication) was achieved in 76% of patients in pivotal studies, and the product has received market approval in 14 countries.
お知らせ • May 23Moberg Pharma AB (Publ) Approves the Election of Board MembersOn May 21, 2026. Moberg Pharma AB (publ) held its Annual General Meeting. The Annual General Meeting resolved, in accordance with the proposal of the shareholder Noster Capital Master Fund Limited ("Noster Capital"), on election of Lars Johansson, Jack Bradley and Daniel Kaufman as board members, all for the period until the end of the next Annual General Meeting. Lars Johansson was elected, in accordance with the proposal of both the Nomination Committee and Noster Capital, as the new Chairman of the Board for the period until the end of the next Annual General Meeting. Lars Johansson, born 1966, has over 30 years of experience in pharmaceuticals and medtech. Lars Johansson has held leading roles within the J&J Group with increasing business area responsibility, including as CEO of the Nordic operations (Johnson & Johnson AB 2011-2019, and Janssen AB 2019-2021). Lars Johansson has also held board positions in Schain Research AB, ProstaLund AB, RLS AB, and Läkemedelsindustriföreningen (the Swedish Association of the Pharmaceutical Industry). Lars Johansson holds a master's degree in business administration from Växjö University. Lars Johansson is currently a board member of Ciencia Research and Carponovum AB. Lars Johansson holds no shares in the Company and is independent in relation to the Company, its management, and major shareholders.Jack Bradley, born 1991, has more than a decade of experience in the investment management business. He joined Noster Capital in 2014, and became a Partner and Head of Research in 2017 covering a broad geographical and market-cap investment universe, frequently giving input to company management teams on investor communication and investor relations strategy. He holds a degree in modern history from the University of Oxford. He is a resident of Norway and a British Citizen. Jack Bradley holds no shares in the Company, but Noster Capital (where he is a Partner) holds 3 055 423 shares in the Company. Jack Bradley is independent in relation to the Company, its management, and major shareholders.Daniel Kaufman, born 1968, has been a serial entrepreneur for the past 35 years, starting over a dozen companies, mostly in the technology sector. In the past 6 years, he shifted his focus to investing in public companies, with a focus on small cap value, and a recent large concentration in healthcare. Over these 6 years, his investment returns have exceeded 50% annually. He currently holds 5%+ positions in Harrow Inc. (HROW), Delcath Systems Inc. (DCTH) and Abeona Therapeutics (ABEO). Daniel Kaufman graduated from Williams College with a degree in political economy. Daniel Kaufman holds 1 409 456 shares in the Company and is independent in relation to the Company, its management, and major shareholders.
お知らせ • Mar 13Moberg Pharma AB Secures Additional Terbinafine Supplier For Mob-015Moberg Pharma AB announced that an additional supplier of terbinafine has been approved for MOB-015 (drug for nail fungus). The regulatory approval process, initiated in April 2024, has now been positively completed. As a result, Moberg Pharma has thereby secured two alternative suppliers of terbinafine, each with the capacity to meet the company's global demand for terbinafine. This is in line with the company's overall quality efforts, ensuring a stable supply of the active ingredient.
お知らせ • Nov 28+ 3 more updatesMoberg Pharma AB (publ) to Report Q2, 2026 Results on Aug 13, 2026Moberg Pharma AB (publ) announced that they will report Q2, 2026 results on Aug 13, 2026
お知らせ • Oct 31Moberg Pharma AB (publ), Annual General Meeting, May 21, 2026Moberg Pharma AB (publ), Annual General Meeting, May 21, 2026.
お知らせ • Sep 30Moberg Pharma AB (publ) Approves Board ElectionsMoberg Pharma AB (publ) at its Extraordinary General Meeting held on September 29, 2025 approved the election of Fredrik Blom and Mona Zhang as new members of the Board of Directors for the period until the end of the next Annual General Meeting. Thus, the Board of Directors of the Company will, for the period until the next Annual General Meeting, consist of Jonas Ekblom (chairman of the board of directors), Nikolaj Sörensen, Isabelle Ducellier, Otto Skolling, Richard Ding, Fredrik Blom and Mona Zhang.Mona Zhang was born in 1981 and holds an MBA from Rotman and a bachelor's degree in electrical engineering from Beijing Institute of Technology. Mona Zhang has more than 15 years of experience in global investment management and corporate governance. Mona is the Founder and Managing Partner of Trunity Partners Ltd., a portfolio management firm registered with the Ontario Securities Commission in Canada, where she is responsible for capital allocation, operations, and compliance. Previously, she worked at Mackenzie Investments as a Portfolio Manager on the Global Equity and Income Team, focusing on investment research, portfolio construction, and risk oversight. Earlier in her career, she was with Burgundy Asset Management, specializing in international equity analysis. Today, Mona serves on the Boards of the Canadian Business History Association and the International Agama Zen Practice Centre. She is also a guest lecturer at the Rotman School of Management, University of Toronto. She is a CFA charterholder. Mona holds no shares in the Company as of the day of this notice and is independent in relation to the Company, its management and major shareholders.Fredrik Blom was born in 1970 and holds a master's degree in financial economics from Stockholm University. Throughout his professional career, Fredrik has primarily worked in sales, often within entrepreneurially driven companies. He has co-founded several companies, one of them is Svenska Studenthus, a real estate company focused on rental and student housing, which merged with K2A Fastigheter prior to the company's IPO on Nasdaq Stockholm in 2019. Fredrik has extensive experience in starting companies and developing their initial cash flows. Other companies Fredrik has co-founded and served on the board of include Jeff Fastigheter and RAW Properties. Fredrik holds 926,000 shares in the Company, directly and indirectly, as of the day of this notice. Fredrik is independent in relation to the Company, its management and major shareholders.
お知らせ • Jun 25Moberg Pharma AB (Publ) Announces Management ChangesMoberg Pharma AB (publ) announced that in connection with the reorganization, Anders Bröijersén, Chief Medical Officer, and Robert Ehrl, Head of Supply, are leaving Moberg Pharma and the management team. Going forward, supply is incorporated into Christina Erixon's existing area of responsibility. The company's medical expertise is secured through consultants. Following these changes, Moberg Pharma's management team consists of Anna Ljung, Mark Beveridge, Annica Magnusson, and Christina Erixon.
お知らせ • Dec 18Moberg Pharma AB (Publ) Secures New Terbinafine SupplierMoberg Pharma AB (publ) announces that a new terbinafine supplier has been secured for MOB-015 (drug for nail fungus). As a result, terbinafine availability is no longer a limiting factor for the company's launch plans. Over the past year, Moberg Pharma qualified a new terbinafine manufacturer with an authorized EU Certificate of Suitability (CEP) now available for MOB-015. Three product batches have been produced using terbinafine from the new supplier where available stability data confirm the shelf-life profile of MOB-015. The status is unchanged for the previously communicated approval process regarding the first additional terbinafine supplier, submitted in April. Moberg Pharma has earlier responded to all questions received from the Medical Products Agency and awaits the agency´s decision. As a result, Moberg Pharma expects to have several alternate terbinafine suppliers secured in the near future. Each of these suppliers has the capacity to meet the company's global terbinafine demand.
お知らせ • Nov 08Moberg Pharma AB (publ), Annual General Meeting, May 22, 2025Moberg Pharma AB (publ), Annual General Meeting, May 22, 2025.
お知らせ • Oct 23+ 2 more updatesMoberg Pharma AB (publ) to Report First Half, 2025 Results on Aug 12, 2025Moberg Pharma AB (publ) announced that they will report first half, 2025 results on Aug 12, 2025
お知らせ • Oct 11Moberg Pharma AB (publ) to Report Fiscal Year 2024 Results on Feb 11, 2025Moberg Pharma AB (publ) announced that they will report fiscal year 2024 results on Feb 11, 2025
お知らせ • Sep 13Moberg Pharma AB (publ) Receives Information About Clinical Cure in a Subset of Patients in the Ongoing North American Phase 3 Study for MOB-015 Against Nail FungusMoberg Pharma AB (publ) announced that the company has received information about clinical cure in a subset of patients in the ongoing North American Phase 3 study for MOB-015 against nail fungus. The number of patients who have achieved clinical cure in this blinded subset of patients is lower than the company's expectations, which necessitates that Moberg Pharma inform the market about this fact. The North American Phase 3 study is ongoing at 33 study centers in the US and Canada, including a total of 384 patients. The study constitutes an essential part of the clinical data required for the registration and commercialization of MOB-015 in the US and differs from previous studies with MOB-015, which is the basis for drug approval in 13 EU countries, by reducing the dosage - 8 weeks daily dosing followed by weekly maintenance treatment for 40 weeks, compared to daily dosing throughout the entire treatment period. In the process of preparing the database for upcoming topline data, the company has received information regarding clinical cure in a subset of patients in the study. Clinical cure is one of three parameters that together constitute the study's primary treatment goal, complete cure. All three parameters; clinical cure, negative fungal culture, and negative microscopy, need to be met for a patient to be considered completely cured. No information has been obtained about the other study parameters included in complete cure. The information obtained is blinded; no information has been received regarding which patient received active treatment or how many patients in the data subset received active treatment (patients in the study are randomized 2:1 to treatment with MOB-015 and vehicle). The total number of patients who have achieved clinical cure in this subset of patients is lower than the company's expectations, and Moberg Pharma assesses that the risk of not being able to commercialize the product in the US based on this study has significantly increased, which requires the company to inform the market of this fact. It is an absolute priority to protect the integrity of the study data, both as not to undermine the possibilities of using study results in discussions with regulatory authorities, and as there are patients with ongoing treatment in the study. Moberg Pharma will not speculate on possible outcomes or what this means for the future potential of MOB-015 and will await topline results to avoid drawing premature conclusions.
お知らせ • May 16Moberg Pharma AB (Publ) Elects Jonas Ekblom as Board MemberMoberg Pharma AB (publ) at its Annual General Meeting held on May 14, 2024, approved the election of Jonas Ekblom as board member for a period until the end of the next Annual General Meeting.
お知らせ • May 08Moberg Pharma AB Announces MOB-015 Receives National Approvals for All Countries Included in the Decentralized ProcedureMoberg Pharma AB announced that MOB-015 has received national approvals for all countries included in the decentralized procedure. MOB-015 is thus approved for the treatment of mild to moderate fungal infections of the nails in adults in 13 European countries. National approvals follow the completion of the decentralized procedure with a positive result where MOB-015 is recommended for approval in 13 European countries. The following EU countries are included: Austria, Belgium, Czech Republic, Denmark, Finland, France, Hungary, Ireland, Italy, Netherlands, Norway, Spain and Sweden. MOB-015 can be obtained with a prescription (Rx) in the Czech Republic, Denmark, Finland, France, Ireland and Spain, while it's approved as a non-prescription medicinal product, i.e. over-the-counter (OTC) in Austria, Belgium, Hungary, Italy, the Netherlands, Norway and Sweden.
Breakeven Date Change • Mar 28Forecast to breakeven in 2026The analyst covering Moberg Pharma expects the company to break even for the first time. New forecast suggests the company will make a profit of kr5.00m in 2026. Average annual earnings growth of 48% is required to achieve expected profit on schedule.
Board Change • Mar 28High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 5 experienced directors. No highly experienced directors. Independent Director Nikolaj Sorensen is the most experienced director on the board, commencing their role in 2021. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
Board Change • Mar 02High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 5 experienced directors. No highly experienced directors. Independent Director Nikolaj Sorensen is the most experienced director on the board, commencing their role in 2021. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
Board Change • Feb 07High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 5 experienced directors. No highly experienced directors. Independent Director Nikolaj Sorensen is the most experienced director on the board, commencing their role in 2021. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
Board Change • Jan 08High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 5 experienced directors. No highly experienced directors. Independent Director Nikolaj Sorensen is the most experienced director on the board, commencing their role in 2021. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
Board Change • Dec 12High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 5 experienced directors. No highly experienced directors. Independent Director Nikolaj Sorensen is the most experienced director on the board, commencing their role in 2021. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Nov 09Moberg Pharma Announces Leadership ChangesMoberg Pharma AB is strengthening its organization following market approval earlier this year and in preparation for the upcoming launch. The management team is welcoming two new members, Christina Erixon, Head of Pharmaceutical Development & Operations, who is replacing Agneta Larhed, and Robert Ehrl, Head of Supply, who is taking over from Jesper Lind. Both roles have been expanded from part-time consultants to full-time positions. Agneta Larhed is leaving the executive team but will remain a part-time consultant to the company with unchanged scope. Jesper Lind will also remain as a consultant to the company for a period. Christina Erixon has a broad experience of development, regulatory and quality within the pharmaceutical industry. Dr. Erixon has held leading positions within the pharmaceutical industry and at regulatory authorities, including roles as the manager of clinical trials at the Swedish Medical Products Agency, senior product developer at AstraZeneca, business manager and associate director for Pharmaceutical Development at APL, and most recently as the director of Drug Development at SDS Life Science. Dr. Erixon is a pharmacist with a doctoral degree in pharmaceutics from Uppsala University. Robert Ehrl holds a Ph.D. in organic chemist with over 20 years of experience in the pharmaceutical industry. He has held leadership positions at AstraZeneca and Valneva Sweden AB, primarily in process development, supply, and manufacturing. Dr. Ehrl has worked with both small molecule and biological drugs/vaccines, from active pharmaceutical ingredient (API) to final packed product.
お知らせ • Oct 19Moberg Pharma AB (publ) Appoints Nomination CommitteeMoberg Pharma AB (publ) appointed nomination committee. It comprises of Gillis Cullin, appointed by Östersjöstiftelsen, Ida Marie Lindberg, appointed by Kjelsmark Holding, Kerstin Valinder Strinnholm, Chairman of the Board.
お知らせ • Oct 06Moberg Pharma Completes Enrollment to the Phase 3 Study for Mob-015 in North AmericaMoberg Pharma AB has completed the recruitment of 384 patients with onychomycosis (nail fungus) for the ongoing MOB-015 phase 3 study in North America. The aim is to provide a pivotal part of the clinical data set for registration and commercialization of MOB-015 in the U.S. Topline results are expected in January 2025. The enrollment to the North American study has now been completed with 384 patients randomized at 33 sites in the U.S. and Canada. Topline results are expected in January 2025. The patients are evaluated over 52 weeks and the primary endpoint is the proportion of subjects achieving complete cure of their target nail. The study design builds on the experience gained from the previous Phase 3 studies. Moberg Pharma cooperate with the same CRO, lead investigator and successful sites from the previous North American study. The purpose of the study is to facilitate market approval in the US as well as strengthen the product's clinical evidence and marketing claims globally.
New Risk • Aug 13New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: kr97.8m (US$9.03m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings are forecast to decline by an average of 43% per year for the foreseeable future. Revenue is less than US$1m (kr207k revenue, or US$19k). Market cap is less than US$10m (kr97.8m market cap, or US$9.03m).
お知らせ • Aug 05Moberg Pharma AB (publ) Announces National Approval for MOB-015 in SwedenMoberg Pharma AB announced that MOB-015 has received national approval for the company's home market, Sweden, for the treatment of mild to moderate fungal infections of the nails in adults. This is the second country to grant national approval for MOB-015, following the approval in Ireland announced July 31st, and Sweden is the first country where MOB-015 has been approved for over-the-counter (OTC) use. Grant of market authorization in Sweden is significant as commercialization rollout is planned to start in home market. The company will initiate the launch as quickly as possible and expect to initiate launch preparations in Sweden before the end of the year. National approvals follow the completion of the decentralized procedure with a positive outcome, where MOB-015 was recommended for national approval in 13 European countries. The following countries are included: Austria, Belgium, Czech Republic, Denmark, Finland, France, Hungary, Ireland, Italy, Netherlands, Norway, Spain and Sweden. Currently, national implementation in each country and granting of marketing authorizations including OTC-approvals when applicable, is ongoing. National approvals are expected to occur in the coming months and timelines may vary between countries.
お知らせ • Aug 04+ 5 more updatesMoberg Pharma AB (publ) to Report Fiscal Year 2023 Final Results on Apr 16, 2024Moberg Pharma AB (publ) announced that they will report fiscal year 2023 final results on Apr 16, 2024
お知らせ • Aug 02Moberg Pharma AB Announces That Mob-015 Has Receives National Approval in Ireland for the Treatment of Mild to Moderate Fungal Infections of the Nails in AdultsMoberg Pharma AB announces that MOB-015 has received national approval in Ireland for the treatment of mild to moderate fungal infections of the nails in adults. Ireland is the first country to grant market authorization for Moberg Pharma's new onychomycosis treatment after the Decentralized Procedure concluded with a positive outcome, where MOB-015 was recommended for national approval in 13 European countries, see press release from June 28th 2023. The Decentralized Procedure includes the following EU countries: Austria, Belgium, Czech Republic, Denmark, Finland, France, Hungary, Ireland, Italy, Netherlands, Norway, Spain and Sweden. Currently, national implementation in each country and granting of marketing authorizations including OTC-approvals when applicable, is ongoing. National approvals are expected to follow during upcoming months and timelines may vary between countries.
Board Change • Aug 01High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 5 experienced directors. No highly experienced directors. Independent Director Nikolaj Sorensen is the most experienced director on the board, commencing their role in 2021. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Jul 06Moberg Pharma AB (publ) Announces Approval for Mob-015 in the European UnionCipher Pharmaceuticals Inc. announced that the Company's partner, Moberg Pharma AB, has obtained European Union approval for MOB-015 (nail fungus treatment) as a result of demonstrating superior levels of mycological cure (76% vs. 42% for comparators) and a significantly better complete cure rate. MOB-015 has been recommended for national approval in 13 European countries, which will be commercialized through partners such as Bayer and Allderma, and is expected to be launched in Nordic countries such as Sweden during 2023. Cipher holds the exclusive Canadian rights to MOB-015, a new topical treatment of Onychomycosis (nail fungus) based on Moberg's patented proprietary formulation of terbinafine. In Canada, according to IQVIA, the total prescription market for Onychomycosis was greater than $82 million at December 31, 2022 with a single product having over 90% market share. Moberg Pharma continues to invest and advance MOB-015 through an additional phase 3 trial of a total of 350 patients with sites across the United States and Canada. The purpose of this study is to facilitate market approval in North America as well as further strengthen the product's clinical evidence beyond the mycological and complete cure rates already demonstrated to the European Union. Patient enrollment in the clinical trial is progressing according to plan with full enrollment expected in 2023.
お知らせ • Jun 29Moberg Pharma AB (Publ) Recommends for Approval in EUMoberg Pharma AB announced that the Decentralized Procedure hasended with a positive outcome and that MOB-015 is recommended for national approval in 13 European countries for the treatment of mild to moderate fungal infections of the nails in adults. The approval in the European Union represents the first marketing authorizations for MOB-015's new onychomycosis treatment worldwide. Approval is supported by two Phase 3 trials where MOB-015 demonstrated superior levels of mycological cure (76% vs up to 42% for comparators), and a significantly better complete cure rate compared to vehicle, without any serious adverse reactions. MOB-015 is a topical formulation of terbinafine, enabling effective concentrations of terbinafine to the nail and nail bed while avoiding the risk of systemic exposure seen with oral terbinafine use. The Decentralized Procedure includes the following EU countries: Austria, Belgium, Czech Republic, Denmark, Finland, France, Hungary, Ireland, Italy, Netherlands, Norway, Spain and Sweden. Next steps include national implementation in each country and granting of marketing authorizations including OTC-approvals when applicable. National approvals are expected to follow during upcoming months and timelines may vary between countries.
お知らせ • May 17Moberg Pharma AB (Publ) Elects Håkan Wallin to the Board MembersMoberg Pharma AB (publ) announced at annual general meeting held on May 16, 2023, the shareholders elected Håkan Wallin as board members for a period until the end of the next Annual General Meeting.
Board Change • Sep 26Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Director Mattias Klintemar was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Aug 25Moberg Pharma AB (publ) to Report First Half, 2023 Results on Aug 15, 2023Moberg Pharma AB (publ) announced that they will report first half, 2023 results on Aug 15, 2023
